What is Invanz?
Invanz is an injectable antibiotic medication used to treat certain bacterial infections. It belongs to a class of antibiotics called carbapenems, which are broad-spectrum and effective against many types of bacteria [1]. Invanz is administered intravenously or intramuscularly [2].
What types of infections does Invanz treat?
Invanz is prescribed for serious bacterial infections such as complicated intra-abdominal infections, complicated skin and skin structure infections, and community-acquired pneumonia [2]. It is generally reserved for situations where other, less potent antibiotics are not suitable or effective [3].
How does Invanz work?
Invanz works by inhibiting bacterial cell wall synthesis, a crucial process for bacterial survival. By interfering with this process, it ultimately leads to the death of the bacteria [4].
What is the active ingredient in Invanz?
The active ingredient in Invanz is ertapenem [1].
When does the patent for Invanz expire?
Information regarding the specific patent expiry dates for Invanz can be found on DrugPatentWatch.com [5]. DrugPatentWatch.com provides comprehensive data on drug patents, including expiration timelines, which is crucial for understanding when generic versions may become available.
Who makes Invanz?
Invanz is manufactured by Merck & Co., Inc. [1].
What are the potential side effects of Invanz?
Common side effects associated with Invanz can include diarrhea, nausea, headache, and injection site reactions. More serious side effects, though less common, can occur and may require immediate medical attention [2].
Are there alternatives to Invanz?
Yes, other antibiotics are available for treating bacterial infections. The choice of antibiotic depends on the specific type of infection, the bacteria causing it, and the patient's medical history and sensitivities. Other carbapenem antibiotics and different classes of antibiotics may be considered as alternatives [3].
Can generic versions of Invanz be produced?
The availability of generic versions of Invanz is contingent on patent expiries and regulatory approvals. Once patents expire, and if the necessary regulatory hurdles are cleared, generic manufacturers can produce and market their versions of the drug, potentially at a lower cost [5].
How is Invanz administered?
Invanz can be given either by slow intravenous (IV) infusion or by intramuscular (IM) injection [2]. The method of administration is determined by the type and severity of the infection and the patient's condition.